Byotrol Plc (AIM: BYOT), a company specializing in infection prevention and control, is thrilled to announce that its unique 24-hour germ-killing surface sanitiser, Byotrol 24 (EPA Reg. Number 83614-1), has
DeepMatter Group PLC (AIM:DMTR) DeepMatter signs multi-year license agreement with the Life Science business sector of Merck
DeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the digital chemistry data and software company, has signed a multiyear database license agreement with Merck, a leading science and technology company,
Futura Medical PLC (AIM:FUM) Highly positive FM71 Phase 3 Study Results
Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation
Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Blockchain technology in the COVID-19 era
Blockchain technology is no longer constrained to the crypto ecosystem, as study has shown its potential for involvement in the healthcare industry.
DeepMatter Group PLC (DMTR.L) Placing, Subscription and Open Offer
DeepMatter Group Plc (AIM: DMTR) (“DeepMatter” the “Company” or the “Group”), the international digital chemistry data company , today announces a placing and subscription to raise gross proceeds o f
DeepMatter Group PLC (DMTR.L) collaborates with Dr. Reddy’s for its DigitalGlassware® platform
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), the international digital chemistry data company, has signed a contract with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), based in Hyderabad, India, for
Deepmatter Group plc (DMTR.L) Half Year Webinar Q and A
The following Q&A comes from the recent DeepMatter Group Plc Half Year Results Webinar
DeepMatter CEO Mark Warne Is Appointed Chairman of Industrial Advisory Board at Imperial College
DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at
AstraZeneca’s Chronic kidney disease Drug Forxiga approved by European Commission
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC). It is now available for chronic kidney disease (CKD), in adults with or without type-2 diabetes (T2D), in the
DeepMatter Group PLC (DMTR.L) Collaboration with the University of Cambridge
DeepMatter collaborates with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies